Synageva

Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board

Retrieved on: 
Monday, October 23, 2023

SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).

Key Points: 
  • SAN JOSE, Calif., Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has appointed Mark A. Goldberg, MD, to its Cancer Business Advisory Board (CBAB).
  • "We are pleased to welcome Dr. Goldberg as the 9th independent member of our CBAB," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
  • "Mark brings valuable clinical expertise in oncology, and his extensive biotechnology executive experience will be an asset to Anixa.
  • Dr. Goldberg received his Bachelor of Arts degree from Harvard College and his medical degree from the Harvard-MIT Program in Health Sciences and Technology.

Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

Retrieved on: 
Wednesday, July 27, 2022

Dr. Tripuraneni serves as the Chief Development Officer of Prothena Corporation plc and brings to the Terns Board of Directors more than 15 years of experience in drug development.

Key Points: 
  • Dr. Tripuraneni serves as the Chief Development Officer of Prothena Corporation plc and brings to the Terns Board of Directors more than 15 years of experience in drug development.
  • Terns approach of discovering and developing next-generation small molecules for clinically de-risked targets in indications with significant unmet need is an exciting strategy, said Dr. Tripuraneni.
  • Dr. Tripuraneni has a breadth of scientific, medical and drug development expertise and I am pleased to have her join our board of directors where she will provide valuable support to our mission, said Sen Sundaram, Chief Executive Officer of Terns.
  • Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer

Retrieved on: 
Tuesday, September 14, 2021

PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (NeuBase or the Company), a biotechnology platform company Drugging the Genome to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Anthony Rossomando, Ph.D., as Chief Technology Officer.

Key Points: 
  • PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (NeuBase or the Company), a biotechnology platform company Drugging the Genome to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Anthony Rossomando, Ph.D., as Chief Technology Officer.
  • "Im impressed with NeuBases PATrOL platform technology for genetic medicines that has demonstrated the ability to differentiate between disease-causing genetic mutations and the normal gene with single-base selectivity," said Dr. Rossomando.
  • At NeuBase, Dr. Rossomando will be responsible for manufacturing and process development, analytical development, and biophysical characterization in support of FDA regulatory submissions.
  • Prior to joining NeuBase, Dr. Rossomando was Chief Process Development Officer at Pinetree Therapeutics, where he oversaw early-stage upstream and downstream process development for bi-specific antibodies for oncology.

U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)

Retrieved on: 
Thursday, June 3, 2021

The FDA has assigned a six-month review period for the resubmitted application and provided November 13, 2021 as the target Prescription Drug User Fee Act (PDUFA) action date.

Key Points: 
  • The FDA has assigned a six-month review period for the resubmitted application and provided November 13, 2021 as the target Prescription Drug User Fee Act (PDUFA) action date.
  • We eagerly look forward to contributing to advances in care through a new therapeutic solution for this challenging rare blood cancer.
  • Ropeginterferon alfa-2b-njft has Orphan Drug designation for the treatment of PV in the United States.
  • Marketed as Besremi in Europe, the product was approved by the European Medicines Agency (EMA) in 2019.

CymaBay Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, February 24, 2021

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.

Key Points: 
  • CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.
  • CymaBay is developing seladelpar, a potent, selective, orally active PPAR agonist for patients with primary biliary cholangitis (PBC).
  • Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA).
  • Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA.

CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 10, 2021

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.

Key Points: 
  • CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.
  • CymaBay is developing seladelpar, a potent, selective, orally active PPAR agonist for patients with primary biliary cholangitis (PBC).
  • Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA).
  • Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA.

CymaBay Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 11, 2020

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.

Key Points: 
  • CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.
  • CymaBay is developing seladelpar, a potent, selective, orally active PPAR agonist for patients with primary biliary cholangitis (PBC).
  • Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA).
  • Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA.

AMRYT RECEIVES POSITIVE OPINION FROM EMA ON ORPHAN DRUG DESIGNATION FOR AP103

Retrieved on: 
Tuesday, September 15, 2020

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Key Points: 
  • Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.
  • In September 2020, Amryt reported positive top line results from its pivotal global phase 3 trial of FILSUVEZ in EB.
  • FILSUVEZ has been granted Rare Pediatric Disease Designation and has also received a Fast Track Designation from the U.S. Food and Drug Administration.
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

AMRYT TO HOST KEY OPINION LEADER CALL ON EPIDERMOLYSIS BULLOSA DISEASE LANDSCAPE

Retrieved on: 
Wednesday, July 29, 2020

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Key Points: 
  • Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.
  • Amryt comprises a strong and growing portfolio of commercial and development assets.
  • FILSUVEZ has been granted Rare Pediatric Disease Designation and has also received a Fast Track Designation from the FDA.
  • Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy

Retrieved on: 
Tuesday, July 21, 2020

REDWOOD CITY, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Thomas Kochy joined the company as vice president, commercial and program strategy.

Key Points: 
  • REDWOOD CITY, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Thomas Kochy joined the company as vice president, commercial and program strategy.
  • In this newly created position, Mr. Kochy will be responsible for leading commercial planning, product strategy, and program management.
  • Prior to joining Adverum, Mr. Kochy served as a strategy consultant in ocular disease areas.
  • Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases.